AACI Webinar | IgniteData: One Platform, Every Study
Focus on research while Advarra enhances compliance, accelerates timelines, and optimizes technology for clinical trial management.
Education
Reducing Avoidable Protocol Amendments by Anticipating Operational Pitfalls Hidden in Clinical Trial Design
This white paper examines four KPIs most impacting timelines and budgets and offers strategies for effective communication and risk mitigation.
Launching Advarra Voice to the Site Community
In this webinar, leaders from cancer centers and biopharma companies will discuss the operational and institutional hurdles sites face and what can be done to address them. The panel will explore practical strategies to reduce burden, improve collaboration, and create a better experience for research staff and patients alike.
Reducing Startup Delays in Oncology Clinical Trials Through Consistent IRB Processes
Traditional clinical trial designs often delay progress due to rigid protocols and frequent amendments. Adaptive and platform trial models introduce flexibility and shared infrastructure, reducing startup delays, cutting costs, and enabling sponsors to conduct faster, more efficient research.
What Are the Different Types of Study Designs?
Traditional clinical trial designs often delay progress due to rigid protocols and frequent amendments. Adaptive and platform trial models introduce flexibility and shared infrastructure, reducing startup delays, cutting costs, and enabling sponsors to conduct faster, more efficient research.
Leveraging Advarra’s Strategic Enablement Services to Improve Research Site Efficiency
In this webinar, leaders from cancer centers and biopharma companies will discuss the operational and institutional hurdles sites face and what can be done to address them. The panel will explore practical strategies to reduce burden, improve collaboration, and create a better experience for research staff and patients alike.
Integrating AI to Balance Scientific Rigor and Real-World Feasibility in Clinical Trial Study Design
Traditional clinical trial designs often delay progress due to rigid protocols and frequent amendments. Adaptive and platform trial models introduce flexibility and shared infrastructure, reducing startup delays, cutting costs, and enabling sponsors to conduct faster, more efficient research.
How Sponsors Can Use Adaptive and Platform Trial Models to Reduce Amendments and Accelerate Study Start-Up
Traditional clinical trial designs often delay progress due to rigid protocols and frequent amendments. Adaptive and platform trial models introduce flexibility and shared infrastructure, reducing startup delays, cutting costs, and enabling sponsors to conduct faster, more efficient research.
Transform Your Site Operations: Optimization Strategies to Maximize Performance
In this webinar, leaders from cancer centers and biopharma companies will discuss the operational and institutional hurdles sites face and what can be done to address them. The panel will explore practical strategies to reduce burden, improve collaboration, and create a better experience for research staff and patients alike.
The Impact of ICH E6(R3) on U.S. and Canadian IRBs
Now that FDA has published the ICH E6(R3) Good Clinical Practice (GCP) guidance, aligning early with these requirements can prepare organizations for the future. ICH E6(R3) encourages ethics review committees to more intelligently apply their resources by enhancing efficiency without compromising participant safety or data integrity particularly regarding continuing review, informed consent, decentralized logistics, and data governance. Sponsors partnering with Advarra can be confident that their studies remain regulation-ready on both sides of the border today and E6(R3)-ready for tomorrow.
CDA Template
This white paper examines four KPIs most impacting timelines and budgets and offers strategies for effective communication and risk mitigation.
Enabling Oncology Site Success: Overcoming Administrative and Operational Barriers to Advance Cancer Research
In this webinar, leaders from cancer centers and biopharma companies will discuss the operational and institutional hurdles sites face and what can be done to address them. The panel will explore practical strategies to reduce burden, improve collaboration, and create a better experience for research staff and patients alike.